Press Releases
  Date Title and Summary View
Jul 27, 2016
Rockville, MD, July 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended June 30, 2016. The Company's management team will host a conference call discussing the Company's financial results and r...
Jun 28, 2016
Rockville, MD, June 28, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer as well as autoimmune disorders and infectious diseases, today announced the closing ...
Jun 10, 2016
Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ROCKVILLE, Maryland, June 10, 2016 (GLOBE NEWSWIRE) --  -- MacroGeni...
May 18, 2016
MacroGenics licenses MGD015 to Janssen$75 Million upfront license fee paid to MacroGenicsMacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit shareMacroGenics may ele...
May 11, 2016
ROCKVILLE, Maryland, May 11, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that cl...
May 10, 2016
ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART®, platform. Pfizer recently dosed a first patient in the Phase...
May 4, 2016
Eight molecules in clinical development, including six in immuno-oncologyOn track for three new IND submissions in 2016-2017Promising pipeline of preclinical candidates shown at recent AACR meeting R...
May 4, 2016
Rockville, MD, May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph....
Apr 27, 2016
ROCKVILLE, Md., April 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call discussing the Company's financial results and recent corporate deve...
Apr 19, 2016
ROCKVILLE, Maryland, April 19, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of ...
Apr 6, 2016
Rockville, MD, April 06, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Jon Wiggin...
Mar 16, 2016
ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced t...
Mar 7, 2016
MGD009 is a bispecific DART molecule that targets B7-H3 and CD3 Redirected T-cell killing of multiple B7-H3-expressing tumor cell lines observed in vitro Dose-dependent inhibition of tumor growth and regression observed in vivo Linear PK and prolonged h...
Feb 29, 2016
Eight molecules in clinical development, including six in immuno-oncology Multi-national Phase 1b/2 gastric cancer study initiated evaluating the combination of margetuximab and pembrolizumab Strong balance sheet supports continued advancement of p...
Feb 16, 2016
ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that on Monday,...
Feb 4, 2016
Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koen...
Dec 2, 2015
ROCKVILLE, Md., Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D....
Nov 7, 2015
Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor typesInitial evidence of T-cell immunomodulatory role ROCKVILLE, Md., Nov. 07, 2015 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal an...
Nov 5, 2015
Second paper published demonstrating DART molecule potential against HIVData support HIV research contract recently awarded to MacroGenics by NIAID ROCKVILLE, Md., Nov. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal anti...
Nov 4, 2015
Bi-specific antibody leadership — fifth DART® molecule (MGD009) enters clinical testingB7-H3 franchise advances — Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1 trial and regional rights regained ...
Nov 4, 2015
ROCKVILLE, Md., Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D....
Oct 28, 2015
Rockville, MD, Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015, the Company will release its financial results for the quarter ended September 30, 2015. The Company's management team will host a conference call discussing the Company's financial results and recent corporate de...
Oct 28, 2015
Server does not exercise option to license rights for enoblituzumab in its specified territoriesMacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD, Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing i...
Oct 22, 2015
ROCKVILLE, MD and KENILWORTH, NJ , Oct. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases, and Merck (NYSE: MRK), ...
Oct 13, 2015
Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trialB7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introducedHIV DART and Trident™ tri-specific platform introduced ROCKVILLE, Md., Oct. 13, 2015 (GLOBE NEWSWIRE) -...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close